A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis

Inclusion Criteria: * Adult (greater than or equal to \[\>=\] 18 years) male or female participants with diagnosis of moderate-to-severe Atopic dermatitis. * Adult participants prescribed lebrikizumab as part of routine/usual care to manage their moderate-to severe Atopic dermatitis. * Willingness and ability to participate in the study; participants must give their written consent to participate. Exclusion Criteria: * Hypersensitivity to the active substances or to any of the excipients of lebrikizumab (Ebglyss®). * Participants with pre-existing helminth infections. These participants should be treated for helminth infection before starting lebrikizumab therapy. * Concomitant use of live and live attenuated vaccines. * Pregnant women, except when the potential benefit justifies the potential risk. * Participants included in a clinical trial at baseline or at any time during the planned study period. * Participants unable to comply with the requirements of the study or who, in the opinion of the study physician, should not participate in the study. * Participants for whom medical chart is inaccessible to physicians to complete baseline data collection.